Project Details


Autoantibody Screening for Autism Autoantibody Screening for Autism The proteomic technologies that have been developed by Dr. Joshua LaBaer allow for the screening of autoantibody markers that subsequently can be used to develop more specific assays with high throughput technologies. The unique technology from this lab provides some strong advantages over other existing technologies to screening 10,000 potential antigens using cDNA clones for in-vitro transcription and translation on the arrays, which avoids the need to express and purify proteins.
Effective start/end date6/1/108/31/11


  • Translational Genomics Research Institute (TGen): $99,639.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.